Pharmacokinetics of cefovecin in cynomolgus macaques (Macaca fascicularis), olive baboons (Papio anubis), and rhesus macaques (Macaca mulatta).

Cefovecin sodium is a long-acting, third-generation, cephalosporin antibiotic approved for the treatment of skin infections in dogs and cats. The pharmacokinetic properties of cefovecin were evaluated in cynomolgus macaques (Macaca fascicularis), olive baboons (Papio anubis), and rhesus macaques (Macaca mulatta) by using a single-dose (8 mg/kg SC) dosing regimen. Plasma cefovecin concentrations were determined by using ultra-performance liquid chromatography with tandem mass spectrometry, and a noncompartmental model was used to determine pharmacokinetic parameters. The half-life of cefovecin was 4.95 ± 1.47 h in cynomolgus macaques, 9.17 ± 1.84 h in olive baboons, and 8.40 ± 2.53 h in rhesus macaques. These values are considerably lower than the half-lives previously published for dogs (133 h) and cats (166 h). The extended half-life of cefovecin in dogs and cats is speculated to be due to active reabsorption of drug in the kidney tubules because plasma clearance is well below the normal glomerular filtration rate. In nonhuman primates, renal clearance rates approximated plasma clearance rates, suggesting that active renal reabsorption of cefovecin does not occur in these species. The pharmacokinetic properties of cefovecin in nonhuman primates are vastly different from the pharmacokinetic properties in dogs and cats, precluding its use as a long-acting antibiotic in nonhuman primates. This study highlights the importance of performing pharmacokinetic studies prior to extralabel drug usage.

Effects of weekly blood collection in C57BL/6 mice.

We assessed hematologic recovery, body weight, and behavior after serial blood collection in 10- to 14-wk-old C57BL/6 mice. Male and female mice (5 to 11 mice for pilot groups, 23 to 35 mice for full study groups) had either 15%, 20%, or 25% of their estimated total blood volume (TBV) collected once weekly for 6 wk. Except for those of the 25% TBV male pilot group, the weights of all mice recovered or increased from one collection to the next. The behavior of all mice, with the exception of the 25% TBV male pilot group, appeared normal throughout the study. Erythrogram value changes from baseline were analyzed at each weekly blood collection. Recovery was defined as the return of mean hemoglobin values to within 2 SD of mean baseline values. According to this definition, mice in the 15% TBV male group and 15%, 20%, and 25% TBV female groups recovered hematologically. To support the statistical definition of recovery, we compared our data with human anemia categories to assess the clinical relevance of the mouse hemoglobin values. On the basis of these data, we conclude that as much as 25% TBV can be collected once weekly from female mice for 6 wk and as much as 15% TBV can be collected once weekly from male mice for 6 wk without producing weight loss, behavioral changes, or clinically significant anemia.